Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The new Cohort Catalogue will facilitate discovery of over 60 neurodegeneration research cohorts from 17 countries across Europe

Woman working at lab bench © John Cairns

Featuring an extensive list of international cohorts across the neurodegenerative disease spectrum, the Cohort Catalogue is a central, open, accessible repository for researchers to discover ongoing studies and search metadata by disease area, biosample availability, imaging and cognitive data, and more.

We are delighted to contribute to this exciting novel biomarker discovery platform.
- Professor Michele Hu

EPND and the University of Oxford

The EPND consortium brings together experts in neurodegeneration research, data science, diagnosis and treatment from 29 public and private organisations. The University of Oxford's involvement is through the Oxford Parkinson's Disease Centre, where Professor Michele Hu is leading collation of UK-wide biosamples from Parkinson's participants including plasma, serum and spinal fluid. 

Funded by the European Union's Innovative Medicines Initiative, EPND aims to accelerate the identification, development, and validation of biomarkers for neurodegenerative diseases, by establishing a data- and sample-sharing platform for collaborative, large-scale research. The Alzheimer's Disease Data Initiative's AD Workbench will power the EPND platform, connecting it to a global network of permissioned users and contributors.

According to Niranjan Bose of Gates Ventures, a member of EPND's Project Management Team, 'EPND is committed to revolutionising scientific breakthroughs in the effort to diagnose, treat, and prevent neurodegenerative diseases. The Cohort Catalogue is a first step towards data and sample sharing, by increasing visibility and awareness of neurodegeneration research studies, to maximise the benefit and impact of neurodegeneration research.'

Currently, 67 research cohorts are included in the Catalogue, with sites in 17 countries across Europe. In total, these neurodegenerative disease cohorts represent 159,675 research participants over 12 different disease areas, with a particular focus on Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies, but also including participants with rarer diseases like amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

'To ensure the Cohort Catalogue would be as useful as possible, we incorporated a vast array of metadata for each cohort, including whether plasma and cerebrospinal fluid samples are included, or MRI or amyloid PET scan images,' said EPND co-Coordinator and clinical epidemiologist, Pieter-Jelle Visser. 'This way, researchers have a single location to easily search – and discover – the complete landscape of neurodegenerative disease cohorts across Europe, and beyond.'

Using the Catalogue, researchers can search and filter cohorts by metadata characteristics, to discover cohorts that could be useful in their own research. Through the Catalogue "contact cohort" feature, researchers can engage with cohorts of interest, to kick-start new collaborations, initiate the sharing of clinical data and biosamples, and partner on funding applications. The Catalogue also offers self-service tools for researchers to add and manage their cohort listings with ease. Additional features and benefits are currently under development to extend the size and scope of the catalogue, and support the research community with enhanced discovery and future request and analysis options.

If you're interested in adding your cohort to the Catalogue, visit the EPND website to register.

The EPND project has received funding from the IMI 2 Joint Undertaking (JU) under grant agreement No. 101034344. The IMI JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Similar stories

Two NDCN students join BNA Scholars Programme

The British Neuroscience Association Scholars Programme was launched in 2021 with a view to improving equality, diversity and inclusion in neuroscience.

Researchers win UK Dementia Research Institute Grand Challenge Award to identify early signs of Alzheimer's

The MRC Brain Network Dynamics Unit has received funding for a multi-year research partnership designed to advance the understanding of early changes to the operations of brain circuits in Alzheimer's disease.

Ophthalmology Conference in Kyiv

On 21 February, Robert MacLaren organised a one-day ophthalmology conference in Kyiv together with Dr Andrii Ruban, President of the Ukrainian Vitreoretinal Society.

Ashmolean turns red for World Encephalitis Day

Our researchers are tackling the devastating brain condition encephalitis.

Bioelectronic implant offers an intelligent therapy to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their 'smart' bioelectronic implants.

Direct evidence of reduced NMDA receptors in people with form of encephalitis

NMDAR-antibody encephalitis is an autoimmune brain condition caused by patient’s own antibodies that bind to NMDA (N-Methyl-D-Aspartate) receptors in the synapses between nerve cells.